Brief: Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology
20/01/2026 14:18
Jan 20 (Reuters) - Illumina Inc ILMN.O: ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIGHT™ ONCOLOGY COMPREHENSIVE, EXPANDING ACCESS TO PRECISION ONCOLOGY ILLUMINA INC - FDA-APPROVED TEST REIMBURSED AT $2,989.55 PER TEST Source text: ID:nPn92JJYFa Further company coverage: ILMN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Illumina
See all newsRoche launches Axelios gene sequencer in a bid to loosen Illumina's grip (updated)
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis
U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner